Masimo ROA 2007-2019 | MASI
Current and historical return on assets (ROA) values for Masimo (MASI) over the last 10 years. Return on assets can be defined as an indicator of how profitable a company is relative to its total assets. Calculated by dividing a company's operating earnings by its total assets. Masimo ROA for the three months ending March 31, 2019 was 15.57%.
| Masimo ROA - Return on Assets Historical Data | |||
|---|---|---|---|
| Date | TTM Net Income | Total Assets | Return on Assets |
| 2019-03-31 | $0.20B | $1.18B | 17.76% |
| 2018-12-31 | $0.19B | $1.16B | 18.44% |
| 2018-09-30 | $0.14B | $1.10B | 14.05% |
| 2018-06-30 | $0.12B | $1.01B | 12.53% |
| 2018-03-31 | $0.12B | $0.95B | 13.02% |
| 2017-12-31 | $0.13B | $0.91B | 13.95% |
| 2017-09-30 | $0.36B | $0.91B | 41.02% |
| 2017-06-30 | $0.35B | $0.90B | 43.41% |
| 2017-03-31 | $0.34B | $0.88B | 45.70% |
| 2016-12-31 | $0.31B | $0.82B | 46.50% |
| 2016-09-30 | $0.11B | $0.64B | 17.85% |
| 2016-06-30 | $0.10B | $0.60B | 16.81% |
| 2016-03-31 | $0.09B | $0.62B | 15.09% |
| 2015-12-31 | $0.08B | $0.60B | 14.19% |
| 2015-09-30 | $0.08B | $0.58B | 13.90% |
| 2015-06-30 | $0.08B | $0.58B | 13.48% |
| 2015-03-31 | $0.07B | $0.58B | 13.08% |
| 2014-12-31 | $0.07B | $0.57B | 14.21% |
| 2014-09-30 | $0.06B | $0.53B | 12.65% |
| 2014-06-30 | $0.06B | $0.50B | 13.59% |
| 2014-03-31 | $0.07B | $0.46B | 15.09% |
| 2013-12-31 | $0.06B | $0.44B | 14.04% |
| 2013-09-30 | $0.06B | $0.43B | 16.12% |
| 2013-06-30 | $0.06B | $0.40B | 15.80% |
| 2013-03-31 | $0.06B | $0.39B | 16.22% |
| 2012-12-31 | $0.06B | $0.38B | 16.30% |
| 2012-09-30 | $0.06B | $0.41B | 16.14% |
| 2012-06-30 | $0.06B | $0.38B | 16.79% |
| 2012-03-31 | $0.06B | $0.38B | 16.85% |
| 2011-12-31 | $0.06B | $0.37B | 18.03% |
| 2011-09-30 | $0.07B | $0.37B | 19.35% |
| 2011-06-30 | $0.07B | $0.35B | 20.35% |
| 2011-03-31 | $0.06B | $0.33B | 20.22% |
| 2010-12-31 | $0.07B | $0.31B | 23.76% |
| 2010-09-30 | $0.07B | $0.33B | 22.27% |
| 2010-06-30 | $0.07B | $0.30B | 21.18% |
| 2010-03-31 | $0.07B | $0.29B | 20.63% |
| 2009-12-31 | $0.05B | $0.36B | 16.15% |
| 2009-09-30 | $0.04B | $0.34B | 12.16% |
| 2009-06-30 | $0.04B | $0.32B | 12.83% |
| 2009-03-31 | $0.04B | $0.31B | 12.86% |
| 2008-12-31 | $0.03B | $0.29B | 12.28% |
| 2008-09-30 | $0.04B | $0.27B | 17.87% |
| 2008-06-30 | $0.04B | $0.25B | 16.19% |
| 2008-03-31 | $0.03B | $0.23B | 13.92% |
| 2007-12-31 | $0.02B | $0.24B | 14.49% |
| 2007-09-30 | $0.02B | $0.23B | 15.04% |
| 2007-06-30 | $0.01B | $0.17B | 27.59% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Instruments Manufacturing | $8.237B | $0.858B |
| Masimo Corporation is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, medical devices, and a wide array of sensors. They believe that Masimo SET helps clinicians monitor in excess of approximately million patients in healthcare settings around the world, and is the pulse oximeter technology used by the top hospitals. Masimo as a private `garage start-up` company because they convinced that the use of adaptive signal processing in the measurement of physiological parameters could solve the problems of low perfusion and motion, which had long plagued in-vivo monitoring and especially pulse oximetry, the measurement of the oxygen saturation of arterial blood. His solution, Masimo SET Measure-through Motion and Low Perfusion pulse oximetry, was shown in a study comparing three pulse oximetry technologies to demonstrate the highest sensitivity and specificity in identifying desaturation events during conditions of motion and low perfusion. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Thermo Fisher Scientific (TMO) | United States | $115.527B | 25.27 |
| Intuitive Surgical (ISRG) | United States | $60.928B | 56.14 |
| Edwards Lifesciences (EW) | United States | $39.801B | 39.77 |
| IDEXX Laboratories (IDXX) | United States | $24.444B | 64.13 |
| Fresenius Medical Care AG KGaA (FMS) | Germany | $24.394B | 16.03 |
| Teleflex (TFX) | United States | $15.460B | 33.50 |
| Olympus (OCPNY) | Japan | $15.407B | 115.28 |
| SONOVA HOLDING (SONVY) | Switzerland | $14.561B | 0.00 |
| Sysmex ADR (SSMXY) | Japan | $14.417B | 38.87 |
| DexCom (DXCM) | United States | $13.759B | 269.84 |
| Hologic (HOLX) | United States | $12.689B | 20.41 |
| STERIS (STE) | Ireland | $12.575B | 30.42 |
| Varian Medical Systems (VAR) | United States | $12.300B | 31.38 |
| ABIOMED (ABMD) | United States | $11.800B | 71.79 |
| Penumbra (PEN) | United States | $6.000B | 254.01 |
| SARTORIUS AG (SARTF) | Germany | $5.850B | 53.60 |
| Elekta AB (EKTAY) | Sweden | $5.153B | 38.83 |
| Integra LifeSciences Holdings (IART) | United States | $4.599B | 21.61 |
| Globus Medical (GMED) | United States | $4.096B | 25.54 |
| Tandem Diabetes Care (TNDM) | United States | $3.740B | 0.00 |
| LivaNova (LIVN) | United Kingdom | $3.605B | 23.50 |
| Wright Medical Group (WMGI) | Netherlands | $3.365B | 667.00 |
| Cantel Medical (CMD) | United States | $3.364B | 34.13 |
| Glaukos (GKOS) | United States | $2.750B | 0.00 |
| Integer Holdings (ITGR) | United States | $2.675B | 19.71 |
| Nihon Kohden (NHNKY) | Japan | $2.449B | 24.64 |
| AVANOS MEDICAL, INC (AVNS) | United States | $2.029B | 32.12 |
| Nevro (NVRO) | United States | $1.983B | 0.00 |
| Inogen (INGN) | United States | $1.373B | 30.40 |
| OPKO Health (OPK) | United States | $1.317B | 0.00 |
| Silk Road Medical (SILK) | United States | $1.239B | 0.00 |
| Veracyte (VCYT) | United States | $1.167B | 0.00 |
| CryoLife (CRY) | United States | $1.116B | 110.70 |
| Accelerate Diagnostics (AXDX) | United States | $1.055B | 0.00 |
| Tactile Systems Technology (TCMD) | United States | $1.032B | 152.33 |
| ORTHOFIX MEDICAL INC (OFIX) | United States | $0.983B | 28.48 |
| Mesa Laboratories (MLAB) | United States | $0.912B | 42.88 |
| Pacific Biosciences Of California (PACB) | United States | $0.910B | 0.00 |
| ViewRay (VRAY) | United States | $0.907B | 0.00 |
| Luminex (LMNX) | United States | $0.882B | 115.35 |
| Natus Medical (BABY) | United States | $0.880B | 20.37 |
| AngioDynamics (ANGO) | United States | $0.810B | 26.55 |
| AxoGen (AXGN) | United States | $0.767B | 0.00 |
| Fluidigm (FLDM) | United States | $0.759B | 0.00 |
| Quotient (QTNT) | Switzerland | $0.696B | 0.00 |
| Intersect ENT (XENT) | United States | $0.651B | 0.00 |
| Corindus Vascular Robotics (CVRS) | United States | $0.581B | 0.00 |
| OrthoPediatrics (KIDS) | United States | $0.541B | 0.00 |
| Si-Bone (SIBN) | United States | $0.483B | 0.00 |
| GenMark Diagnostics (GNMK) | United States | $0.361B | 0.00 |
| Oxford Immunotec Global (OXFD) | United Kingdom | $0.354B | 18.99 |
| RTI Surgical (RTIX) | United States | $0.312B | 38.36 |
| Accuray (ARAY) | United States | $0.309B | 0.00 |
| TransEnterix (TRXC) | United States | $0.304B | 0.00 |
| Semler Scientific (SMLR) | United States | $0.289B | 57.37 |
| SeaSpine Holdings (SPNE) | United States | $0.245B | 0.00 |
| Neuronetics (STIM) | United States | $0.235B | 0.00 |
| ConforMIS (CFMS) | United States | $0.231B | 0.00 |
| Alphatec Holdings (ATEC) | United States | $0.208B | 0.00 |
| IRadimed (IRMD) | United States | $0.203B | 38.64 |
| CRH Medical (CRHM) | Canada | $0.201B | 69.75 |
| Sientra (SIEN) | United States | $0.180B | 0.00 |
| Stereotaxis (STXS) | United States | $0.172B | 0.00 |
| Second Sight Medical Products (EYES) | United States | $0.100B | 0.00 |
| Ekso Bionics Holdings (EKSO) | United States | $0.093B | 0.00 |
| Sensus Healthcare (SRTS) | United States | $0.088B | 0.00 |
| Vermillion (VRML) | United States | $0.086B | 0.00 |
| EDAP TMS S.A (EDAP) | France | $0.078B | 0.00 |
| Covalon Technologies (CVALF) | Canada | $0.070B | 0.00 |
| T2 Biosystems (TTOO) | United States | $0.069B | 0.00 |
| Apollo Endosurgery (APEN) | United States | $0.066B | 0.00 |
| Spectral Diagnostics (EDTXF) | Canada | $0.066B | 0.00 |
| Helius Medical Technologies (HSDT) | United States | $0.053B | 0.00 |
